Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

Presentation TCT 2017

SENIOR and Shorter DAPT Studies: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Olivier Varenne

November 01, 2017

Presentation TCT 2017

CULPRIT-SHOCK: Appreciation and Critique

Presenter: Martin B. Leon, Marco Valgimigli, Cindy L. Grines

November 01, 2017

Presentation TCT 2017

CULPRIT-SHOCK: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Georg Fuernau, MD

November 01, 2017

Presentation TCT 2017

CULPRIT-SHOCK: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Georg Fuernau, MD

November 01, 2017

Presentation TCT 2017

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Appreciation and Critique

Presenter: Martin B. Leon, Marco Valgimigli, Giulio G. Stefanini

November 01, 2017

Presentation TCT 2017

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Gregg W. Stone

November 01, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem

October 30, 2017

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Radial Approach and Renal Protection: A MATRIX Trial Analysis

Presenter: Prashant Kaul, Jennifer A. Tremmel, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

DAPT Duration: Individualized vs Generalized Approach

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Marco Valgimigli

October 29, 2017

News Conference News ESC 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

Todd Neale

September 01, 2017

News Daily News

Use of DAPT Score Following PCI Validated in PRODIGY Study

Yael L. Maxwell

June 12, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

Todd Neale

March 10, 2017

Presentation JIM 2017

The FASTER the GPI infusion…the better the reperfusion

Presenter: Marco Valgimigli

February 10, 2017

Advertisement

SENIOR and Shorter DAPT Studies: Highlights Summary

CULPRIT-SHOCK: Appreciation and Critique

CULPRIT-SHOCK: Highlights Summary

CULPRIT-SHOCK: Highlights Summary

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Appreciation and Critique

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Highlights Summary

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Switching to and From Cangrelor: When and How?

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Radial Approach and Renal Protection: A MATRIX Trial Analysis

DAPT Duration: Individualized vs Generalized Approach

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

Use of DAPT Score Following PCI Validated in PRODIGY Study

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

The FASTER the GPI infusion…the better the reperfusion

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content